Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem
- 1 February 2021
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 324, 255-260
Abstract
No abstract availableKeywords
Funding Information
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
This publication has 43 references indexed in Scilit:
- Boosted protease inhibitors and the electrocardiographic measures of QT and PR durationsAIDS, 2011
- Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteersJournal of Antimicrobial Chemotherapy, 2010
- Extreme bradycardia due to multiple drug–drug interactions in a patient with HIV post‐exposure prophylaxis containing lopinavir–ritonavirBritish Journal of Clinical Pharmacology, 2010
- TWIN PRETERM NEONATES WITH CARDIAC TOXICITY RELATED TO LOPINAVIR/RITONAVIR THERAPYThe Pediatric Infectious Disease Journal, 2009
- Electrocardiogram Abnormalities with Atazanavir and Lopinavir/RitonavirHIV Research & Clinical Practice, 2009
- Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infectionSexual Health, 2009
- Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT studyJournal of the International AIDS Society, 2008
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- Bradycardia–tachycardia syndrome induced by lopinavir–ritonavir in a patient with AIDSAIDS, 2005
- Is Gender a Risk Factor for Adverse Drug Reactions?Drug Safety, 2001